To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

To demonstrate the relative bioavailability of Divalproex Sodium 500 mg delayed release tablets under fed conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sandoz
• Treatments: Valproic Acid

Criteria

Inclusion Criteria:

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

• Positive test results for HIV or hepatitis B or C.

• Treatment for drug or alcohol dependence.